Longeveron (LGVN) Enterprise Value (2021 - 2026)
Longeveron (LGVN) posted quarterly Enterprise Value of -$15.8 million for Q1 2026, down 9.99% year-over-year from -$17.5 million in Q1 2025, and down 238.08% quarter-over-quarter from -$4.7 million in Q4 2025.
Longeveron (LGVN) Enterprise Value (2021 - 2026) Analysis & Trends
Longeveron's Enterprise Value history runs 6 years deep, the most recent figure standing at -$15.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 9.99% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$15.8 million (down 9.99% YoY), while the FY2025 annual figure was -$4.7 million, up 75.76% from the prior year.
- Enterprise Value for Q1 2026 stood at -$15.8 million, down from -$4.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.3 million in Q1 2024, with the low at -$22.8 million in Q3 2024.
- The 5-year median for Enterprise Value is -$9.8 million (2025), against an average of -$10.8 million.
- Peak annual rise in Enterprise Value reached 75.76% in 2025, while the deepest fall reached 525.36% in 2025.
- Longeveron's Enterprise Value stood at -$19.7 million in 2022, then jumped by 72.73% to -$5.4 million in 2023, then plunged by 258.74% to -$19.2 million in 2024, then surged by 75.76% to -$4.7 million in 2025, then slumped by 238.08% to -$15.8 million in 2026.
- Business Quant data shows LGVN's Enterprise Value at -$15.8 million in Q1 2026, -$4.7 million in Q4 2025, and -$9.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -10.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.10 Mn |
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Sep 30, 2025 | -9.24 Mn |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | -14.33 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -22.78 Mn |
| Jun 30, 2024 | -12.40 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | -5.36 Mn |
| Sep 30, 2023 | -3.93 Mn |
| Jun 30, 2023 | -8.66 Mn |
| Mar 31, 2023 | -2.30 Mn |
| Dec 31, 2022 | -19.66 Mn |
| Dec 31, 2021 | -35.04 Mn |